Adaptive Biotechnologies Corporation
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2019 | — | $571.0M | $96.6M |
| FY2020 | — | $743.3M | $123.4M |
| FY2021 | — | $604.0M | $139.1M |
| FY2022 | $125.4M | $464.2M | $90.0M |
| FY2023 | $130.7M | $308.4M | $65.1M |
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2019 | — | $571.0M | $96.6M |
| FY2020 | — | $743.3M | $123.4M |
| FY2021 | — | $604.0M | $139.1M |
| FY2022 | $125.4M | $464.2M | $90.0M |
| FY2023 | $130.7M | $308.4M | $65.1M |